Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus HALOTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus HALOTEX.
AMPHOTEC vs HALOTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal